<DOC>
	<DOCNO>NCT02187042</DOCNO>
	<brief_summary>220 patient metastatic and/or advance renal cell carcinoma treat sunitinib ( Sutent ) randomize two arm : - Control arm : Followed standard care - Experimental arm : Followed standard care plus call center Principal assumption : reduce percentage adverse event grade 3 , 4 20 % control arm ( 60 % ) experimental arm .</brief_summary>
	<brief_title>Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib ( Sutent ) In First Line</brief_title>
	<detailed_description>Observational study , prospective randomize metastatic and/or advance renal cell carcinoma patient two arm - Control arm : Followed standard care - Experimental arm : Followed standard care plus call center All eligible metastatic and/or advance renal cell carcinoma patient see investigator participate study enrol randomize study . If eligible patient enrol study , oncologists complete point registry non inclusion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Metastatic and/or advance renal cell carcinoma patient treat sunitinib first line accord summary product characteristic Resolution adverse event ( grade â‰¤ 1 accord Common Terminology Criteria Adverse Events v 4.3 June 2010 ) prior treatment radiotherapy and/or surgery Patient follow 6 month Patient sign consent form Patient affiliate national health service Sexually active fertile subject partner must agree use medically accept method contraception course study 28 day last dose study treatment Patient participate another clinical study Patient take charge home help service Patient brain metastasis treat symptomatic Patient Eastern Cooperative Oncology Group inclusion &gt; 2 Patient rate serum creatinine &gt; 1.5 time upper limit normal Patient rate bilirubin &gt; 2 mg/dl Patient rate aspartate transaminase ( ASAT ) alanine transaminase ( ALAT ) &gt; 2.5 time upper limit normal &gt; 5 time upper limit normal patient hepatic metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>call center</keyword>
	<keyword>management patient</keyword>
	<keyword>nurse</keyword>
	<keyword>metastatic renal carcinoma</keyword>
</DOC>